Impaired Pre-Transplant Fev1 is Associated With Reduced Overall and Disease Free Survival Following Allogeneic Transplant for Acute Myelogenous Leukemia  by Magenau, J. et al.
60 Poster Session-Inot in CR at SCT. Randomized studies are needed to determine
the role of RIC in MDS/AML pts in CR at SCT. The novel mod-
MAC regimens are relatively well tolerated even in pts not eligible
for MAC and may be more effective than standard RIC in refrac-
tory disease.159
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT) FOR PROLYM-
PHOCYTIC LEUKEMIA (PLL)
Kalaycio, M., Kukreja, M., Szer, J., Woolfrey, A., Cortes, J., Arora, M.
CIBMTR, Milwaukee, WI
Although PLL is indolent in some people, most affected persons
die within 1 year. Several case reports suggest a benefit to allogeneic
HCT.We sought to determine if this hypothesis is correct in the ob-
servational database of the Center for International Blood and Mar-
row Transplant Research.We retrospectively reviewed data from 47
subjects transplanted between1995 and 2006. Median age was 54 y
(range, 30–75 y). Karnofsky performance score was .80% in 30
(75%). Immunophenotype was B-cell in 11 (23%), T-cell in 21
(45%), and unknown in 15 (32%). Six patients (13%) had a splenec-
tomy and 16 (36%) were in complete remission (CR) at the time of
transplant. Donors were HLA-matched siblings or well-matched
unrelated donors in 34 (70%). Conditioning regimens included
high-doses of radiation or busulfan in 19 (40%), low-doses in 14
(30%), and neither in 14 (30%) includingmelphalan (N5 7) and flu-
darabine-containing regimens (N5 6). Grafts were blood cells in 31
(66%). Grade 2–4 acute graft versus host disease (GvHD) developed
in 52% (95% confidence interval (CI) 38–66%) of transplant recip-
ients. 1 year incidence of chronic GVHD was 42% (CI 28–57%).
Treatment related mortality (TRM) was 28% (CI 16–42%) and oc-
curred within 1 yr of transplant. Common causes of non-relapse
mortality were infection (N 5 4; 12%), GvHD (N 5 5; 15%), and
pneumonitis/ARDS (n 5 3;9%). PLL progression was the most
common cause of death (N 5 16; 49%). Median progression-free
survival (PFS) and overall survival (OS) is 5 and 11 mos, respectively.
Median PFS for 16 subjects transplanted in CR is 8.9 mo. Median
PFS for patients with matched siblings or well-matched donors
(N 5 34) is 5.2 mo. With a median follow-up of survivors of 13
mos, the 1y PFS and OS is 33% (CI 20–47%) and 48% (CI 33–
62%), respectively. At 2y, the PFS is also 33% (CI 20–47%) and
OS is 35% (CI 21–50%). These data provide information on antic-
ipated outcomes of allotransplants for PLL.160
PROLONGED SURVIVAL IN ADULTS WITH ACUTE LYMPHOBLASTIC
LEUKEMIA (ALL) FOLLOWING REDUCED INTENSITY CONDITIONING
WITH CORD BLOOD OR SIBLING DONOR TRANSPLANTATION
Bachanova, V., Verneris, M.R., Brunstein, C., Weisdorf, D. University of
Minnesota, Minneapolis,, MN
The optimal therapy for adult ALL patients.35 years or intoler-
ant of myeloablative allotransplantation is uncertain. Twenty-two
adult ALL patients received reduced intensity conditioning (RIC)
followed by allogeneic transplantation. All patients were high risk
with 64% having Ph1 ALL and 46% in $2nd remission, 20/22
were in cytogenetic CR. Following a uniform preparative regimen
(fludarabine 40 mg/m2/day  5, cyclophosphamide 50 mg/kg/day
and 200 cGy total body irradiation) patients received either umbilical
cord (UCB, n5 18) or matched related (MRD, n5 4) donor grafts.
All patients reached neutrophil engraftment (median 10 days) and
100% donor chimerism (median day 23). Overall survival, treatment
related mortality and relapse were 50% (95% confidence interval
[CI], 27–73%), 27% (95%CI, 9–45%), 36% (95%CI, 14–58%) at
3 years, respectively. There were no relapses beyond 2 years. OS,
TRM and relapse following cord blood HCT were 49% (95%CI,
23–75%), 28% (95%CI, 8–48%) and 33% (95%CI, 9–57%). The
cumulative incidence of acute (grade II-IV) and chronic graft versus
host disease was 55% and 45%.HCT inCR1 led to less TRM (8%vs
50%, p\0.04) and improved OS (81% vs 15%, p\0.01). For ALL
adults in CR1, RIC allografting using UCB or MRD results in
modest TRM, limited risk of relapse and promising leukemia-free
survival.161
ADOPTIVE T CELL THERAPY USING EDUCATED T CELLS GENERATED BY
THE SEQUENTIAL STIMULATION WITH DC/TUMOR FUSION CELLS AND
ANTI-CD3/CD28
Rosenblatt, J.1, Vasir, B.2, Wu, Z.2, Zarwan, C.1, Stone, R.2,
Bissonnette, A.2, Friedman, T.2, Stevenson, K.2, Neuberg, D.2,
Mills, H.1, Glotzbecker, B.1, Levine, J.D.1, Joyce, R.1, Boussiotis, V.1,
Tzachanis, D.1, Spentzos, D.1, Konstantinopoulos, P.1, Kufe, D.2,
Avigan, D.1 1Beth Israel Deaconess Medical Center, Boston, MA;
2Dana Farber Cancer Institute, Boston, MA
Acute leukemia is susceptible to T cell mediated killing as evi-
denced by the graft versus disease effect following allogeneic trans-
plantation. The development of adoptive immunotherapy to more
selectively target tumor cells is an area of interest. Ligation of the
CD3/CD28 complex results in expansion of T cells ex vivo with
a phenotype that is dependent on the immunologic milieu during
stimulation. We have developed a cancer vaccine in which autolo-
gous tumor cells are fused with dendritic cells (DCs). We postu-
lated that stimulation with fusions followed by anti-CD3/CD28
would result in the expansion of activated T cells targeting tumor
antigens. Tumor was obtained from peripheral blood or bone mar-
row of patients with AML. DCs were generated from adherent
mononuclear cells cultured with rhIL-4, GM-CSF and TNFand
fused with tumor cells by coculture in polyethylene glycol. T cells
were stimulated by fusions prior to or following exposure to
antiCD3/CD28 antibody coated plates. Stimulation by fusions fol-
lowed by anti-CD3/CD28 resulted in the synergistic expansion of
T cells, manifested by a greater stimulation index (SI) compared
to stimulation by either pathway alone (SI 8.2 versus 3.3 with fu-
sions alone). A rise in CD41/CD251 cells was noted following se-
quential stimulation with fusions and anti-CD3/CD28 (9.3% vs.
2.7% with fusions alone). An higher percentage of CD41/
CD251 cells expressed IFNg when exposed to fusions followed
by anti-CD3/CD28 (7% compared to 2% with fusions alone). As
compared to un-stimulated T cells, stimulation with fusions or
anti-CD3/CD28 resulted in a 3.3 and 3.8 fold increase in CD81
T cells expressing granzyme B, respectively. In contrast, sequential
stimulation with fusions and anti-CD3/CD28 induced a 19-fold ex-
pansion of granzyme B1 cells consistent with enhanced cytolytic
capacity. In spectratyping analysis, T cells undergoing sequential
stimulation with fusions and anti-CD3CD28 demonstrate greater
skewing of CDR3-size usage in the T cell receptor as compared
to T cells stimulated by fusions or anti-CD3/CD28 alone. The pat-
tern of gene expression in T cells stimulated sequentially by fusions
and anti-CD3CD28 is being assessed. In conclusion, sequential
stimulation of T cells by fusions and anti-CD3/CD28 results in
the expansion of tumor reactive activated T cells. A clinical trial
evaluating the use of T cells generated by sequential stimulation
with DC/tumor fusions and anti-CD3CD28 for patients with acute
leukemia is planned.162
IMPAIRED PRE-TRANSPLANT FEV1 IS ASSOCIATED WITH REDUCED
OVERALL AND DISEASE FREE SURVIVAL FOLLOWING ALLOGENEIC
TRANSPLANT FOR ACUTE MYELOGENOUS LEUKEMIA
Magenau, J.1, Maslak, J.2, Mineishi, S.1, Digiandamenico, S.2,
Braun, T.1, Levine, J.E.1, Yanik, G.A.1 1University of Michigan, Ann
Arbor, MI; 2University of Michigan, Ann Arbor, MI
Introduction: Pulmonary function testing (PFT) is routinely per-
formed prior to allogeneic hematopoetic stem cell transplant
(HSCT), but its relationship to survival is poorly described. In this
report, the post-transplant survival outcomes of Acute Myelogenous
Leukemia (AML) patients are examined with respect to pre-trans-
plant pulmonary function.
Methods: Two hundred fifty one patients with AML receiving
HSCT between January 2001 and May 2008 at the University of
Michigan were retrospectively analyzed for pre-transplant PFTs by
forced expiratory volume at one second (FEV1), forced vital capacity
(FVC), and diffusion capacity (DLCO). PFT function parameters
FEV1 ($80% vs. \80%), FVC ($80% vs. \80%), and DLCO
($65% vs. \65%) were correlated with overall (OS) and disease
free survival (DFS). Using a multivariate Cox regression analysis,
OS and DFS were modeled for the following risk factors: age at
Poster Session-I 61transplant, disease status, donor type, absolute neutrophil count, ab-
solute lymphocyte count (ALC), presence of circulating blasts, stem
cell source, CD341 cell dose, conditioning intensity, cytogenetic
profile, antecedent myelodysplastic syndrome (MDS) or secondary
AML, and development of acute graft versus host disease
(GVHD). Deaths attributable to relapse versus non-relapse causes
were recorded for each PFT group.
Results: Pre-transplant characteristics included a median age of
49 yrs (range 7–69 yrs), intermediate/high risk cytogenetics (95%),
CR1/ CR2 (93%), circulating blasts (8%), full intensity conditioning
(78%), related donor (48%), FEV1\ 80% (12%), FVC \ 80%
(15%), and DLCO\ 65% (34%). Diminished FEV1 (\ 80%), dis-
ease status, regimen intensity, ALC, and circulating blasts were asso-
ciated with a significantly reduced disease free survival (Table).
Though FEV1\ 80% and FVC\ 80% were both associated with
a poor DFS (p 5 0.001 and p 5 0.027) and OS (p 5 0.005 and
p5 0.017) by univariate analysis, only FEV1\80% remained asso-
ciated with DFS and OS in the multivariate Cox regression analysis.
Pre-transplant DLCO\ 65% did not reach significance for either
DFS or OS by univariate or multivariate analysis. Relapse related
mortality was more common in patients with a pre-transplant
FEV1 $80% (50%) then patients with an FEV1\80% (39%).
Conclusion: Pre-transplant FEV1\ 80% is associated with re-
duced DFS and OS in patients with AML undergoing allogeneic
HSCT and may provide valuable prognostic information in pre-
transplant evaluations.
Pre-Transplant Factors Associated with Survival
Overall Survival Disease Free SurvivalRisk Factor Risk Ratio p-value Risk Ratio p-valueFEV1$ 80 0.519 0.019 0.467 0.006
Disease Status1 2.144 0.000 1.924 0.004
Regimen Intensity 2 2.174 0.001 2.047 0.003
ALC $ 0.5 0.513 0.003 0.544 0.008
Peripheral Blast 13 - - 2.220 0.0181Disease .CR2 or in relapse.
2reduced intensity conditioning (RIC).
3not associated with overall survival.163
ALLOGENEIC STEM CELL TRANSPLANTION IN RELAPSED/REFRACTORY
ACUTE LEUKEMIA: A LONG TERM SINGLE INSTITUTION EXPERIENCE
Go, A., Stiff, P.J., Parthasarathy, M., Rodriguez, T.E., Smith, S.E.,
Brush, M., Kiley, K., Payan, M., Porter, N., Volle, M., Vesole, D.H.
Loyola University Medical Center, Maywood, IL
Introduction: The clinical outcomes of relapsed and refractory
acute myeloid leukemia (AML) and acute lymphoblastic leukemia
(ALL) are dismal in adults treated with conventional therapy. The
majority of patients with relapsed ALL and AML who are subse-
quently cured are transplanted in second remission or, occasionally,
beyond second complete remission. A minority of patients, in the
range of 10 to 20%, with relapsed/refractory disease are cured by
an allogeneic bone marrow transplant.
Objective: We retrospectively examined 137 patients with re-
lapsed and/or refractory acute leukemia who were recipients of allo-
geneic transplants (matched related [MRD], matched unrelated
[MUD] and umbilical cord blood [UCB]) at our center from August
1986 to August 2008 to determine the outcome in advanced leuke-
mia.
Methods: One hundred thirty seven patients (AML, n 5 95 and
ALL, n 5 42) received allogeneic transplants including: 75 MRD,
39MUD, and 23UCB.Conditioning regimens weremostlymyeloa-
blative using combinations of cyclophosphamide(Cy), busulfan (Bu),
etoposide(VP) and total body irradiation (TBI): TBI/Cy/VP, n5 31;
TBI/Cy, n5 66; other TBI based, n5 10; Bu/Cy, n5 20;.other, n5
9. GVHD prophylaxis varied over the years but included a calci-
neurin inhibitor with methotrexate for MUD/MRD transplants
and steroids for UCB transplants.Results:The median age at transplant was 45 years for AML (13–
72) and 32 years for ALL (1–66). Results are shown in the table below
and compared to the survival data (extrapolated) from the NMDP/
CIBMTR database.
Table 1 Transplant Outcomes in Relapsed and/or Refractory
Acute Leukemia
NMDP/ NMDP/N100 day
survival1 year
survival2 year
survivalCIBMTR
-MRDCIBMTR
-MUD1 year–
2year1 year–
2yearAML 95 62% 33% 27%MRD 75 68% 30% 22% 40%–30%MUD 39 54% 30% 26% 30%–20%UCB 23 48% 26% 16%Survival by Age\40yrs 35 74% 48% 38%
40–55yrs 36 56% 29% 26%.55yrs 24 54% 12% 12%ALL 42 57% 21% 11% 35%–20% 30%–15%Conclusion: Our single institutional experience in allogeneic
transplantation for advanced leukemia appears comparable to the
CIBMTR/NMDP database. Younger patients had the best out-
comes. MUD recipients had comparable outcomes to MRD. There-
fore, we recommend that younger patients with advanced leukemia
be strongly considered for allogeneic transplant, regardless of stem
cell source, as the only potentially curative option.164
SELECTIVE REPROGRAMMING OF CD19-SPECIFIC T CELLS WITH IL-21
AND CD28 SIGNALING FOR ADOPTIVE IMMUNOTHERAPY OF ACUTE
LYMPHOBLASTIC LEUKEMIA
Singh, H.1, Huls, M.H.1, Dawson, M.J.1, Mi, T.1, Lee, D.A.1,
Kebriaei, P.2, Shpall, E.J.2, Hackett, P.B.3, June, C.H.4,
Champlin, R.E.2, Cooper, L.J.N.1 1U.T. M.D. Anderson Cancer Center,
Houston, TX; 2U.T.M.D. Anderson Cancer Center, Houston, TX; 3Uni-
versity of Minnesota, St Paul, MN; 4University of Pennsylvania Cancer
Center, Philadelphia, PA
Adoptive transfer of T cells has been used to treat and prevent ma-
lignancies and opportunistic infections. To improve therapuetic effi-
cacy, investigators initially redirected specificity through the
introduction of immunoreceptors. Early-phase trials are now under-
way to demonstrate the safety and feasibility ofCD19-specific chime-
ric antigen receptors (CARs)which recognize antigen independent of
MHC. However, it is recognized that improving in vivo persistence
will be needed to enhance therapeutic potential of CAR1 T cells.
To this end we developed two approaches: (i) intrinsic: altering the
signalling pathway of T cells to improve persistence and (ii) extrinsic:
altering the culturing milieu to numerically expand CAR1 T cells
with a proliferative advantage. Previously we reported on a 2nd gen-
eration CAR (designated CD19RCD28) which activates T cells
through CD3-z and CD28 endodomains, to sustain proliferation of
CD19-specific T cells. One extrinsic factor to be assessed is IL-21,
a member of the common g-chain receptor cytokine family that can
signal CD81T cells in conjunction with CD28 to support prolifera-
tion and acquisition of desired effector functions.Wenow report that
the addition of exogenous IL-21 favors the microenvironment to se-
lectively propagate CAR1 CD81 T cells with ability to kill CD191
tumor targets. To evaluate this role for IL-21, peripheral blood-de-
rived T cells were electroporated with CD19RCD28 CAR expressed
as a Sleeping Beauty (SB) transposon and propagated in the presence of
IL-2 and/or IL-21 on g-irradiated CD191 artificial antigen present-
ing cells (aAPC). There was a selective outgrowth of CAR1CD81T
cells when IL-21 was present in the culture medium, compared with
predominant outgrowth of CAR1CD41T cells when IL-21 was ab-
sent (Table).The propagatedCAR1Tcells producedmore IFN-g in
response toCD191 stimulator cells compared to cells cultured in par-
allel only on IL-2, and displayed a centralmemory surface phenotype
while retaining an ability to exhibit CD19-dependent cytolysis.
